411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients

• Lilian Siu,
• Jacob Thomas,
• Diana Hanna,
• Anthony El-Khoueiry,
• Nilofer Azad,
• Lewis Bender,
• Ian Walters,
• Giles Whalen,
• Matthew Ingham

Affiliations

Lilian Siu

2Princess Margaret Cancer Centre, Toronto, Canada

Jacob Thomas

11Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Diana Hanna

41Division of Medical Oncology, University of Southern California, Hoag Family Cancer Institute, Newport Beach, California, USA

Anthony El-Khoueiry

1University of Southern California, Los Angeles, CA, USA

Nilofer Azad

3Johns Hopkins, Chevy Chase, MD, USA

Lewis Bender

4Intensity Therapeutics, Westport, CT, USA

Ian Walters

4Intensity Therapeutics, Westport, CT, USA

Giles Whalen

5University of Massachussetts, Worcester, MA, USA

Matthew Ingham

6Columbia University, New York, NY, USA